TLDR The combination therapy was effective and well-tolerated, especially in young patients.
The study evaluated the combination of 308-nm excimer phototherapy and monthly intramuscular triamcinolone acetonide (TAC) for treating resistant alopecia totalis (AT) in 10 patients, showing a 90% overall response rate. Complete hair regrowth was achieved in 40% of patients, with younger patients and those with a shorter disease history responding better. Adverse effects were mild and temporary, and recurrence was noted in 22.2% of responders during the 8-12 month follow-up. The combination therapy was effective and well-tolerated, particularly in young patients, but the small sample size limited the generalizability of the results, indicating a need for larger randomized controlled trials.
148 citations,
December 2018 in “Journal of autoimmunity” Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.
44 citations,
April 2017 in “International Journal of Dermatology” No treatment is completely effective for alopecia totalis and alopecia universalis.
12 citations,
July 2016 in “Journal of dermatology” Intramuscular triamcinolone acetonide is an effective treatment for severe alopecia areata, especially in males.
80 citations,
November 1975 in “Acta dermato-venereologica” Large doses of glucocorticoids are not suitable for general use in treating severe alopecia areata due to inconsistent results and risks.
1 citations,
January 2023 in “Przegląd Dermatologiczny” The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
4 citations,
September 2011 in “Expert Review of Dermatology” Various treatments exist for alopecia areata, but none are completely satisfactory; choice depends on age, disease extent, and preference.
85 citations,
October 2012 in “Dermatologic Clinics” Alopecia Areata is an autoimmune condition often starting before age 20, with varied treatment success and a need for personalized treatment plans.
2 citations,
March 2015 in “Expert opinion on orphan drugs” New treatments for hair loss show promise but need more research to confirm safety and effectiveness.
23 citations,
October 2020 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” Tailored treatments for alopecia areata are recommended based on severity and patient needs.
